Measuring blood levels of clusterin may help in early diagnosis and monitoring of diabetes complications, especially diabetic nephropathy, and cardiovascular illnesses, which are linked to elevated blood levels of this protein . Research has demonstrated a correlation between the severity of a disease and clusterin levels; higher levels may signify a more advanced disease or more significant tissue damage . Monitoring clusterin levels may reveal information about the efficacy of treatment measures and act as a predictive biomarker for the onset of problems in diabetes patients . To increase diagnostic accuracy and prediction value for diabetes complications, measurement methodologies must be standardized, large-scale validation studies must be conducted, and clustering must be integrated with other biomarkers for clinical use .